RT Journal Article
SR Electronic
T1 Evaluation of the Access Bio CareStart™ rapid SARS-CoV-2 antigen test in asymptomatic individuals tested at a community mass-testing program in Western Massachusetts
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.17.21259109
DO 10.1101/2021.06.17.21259109
A1 Suliman, Sara
A1 Matias, Wilfredo R.
A1 Fulcher, Isabel R
A1 Molano, Francisco J.
A1 Collins, Shannon
A1 Uceta, Elizabeth
A1 Zhu, Jack
A1 Paxton, Ryan M.
A1 Gonsalves, Sean F.
A1 Harden, Maegan V.
A1 Fisher, Marissa
A1 Meldrim, Jim
A1 Gabriel, Stacey
A1 Franke, Molly F.
A1 Hung, Deborah T.
A1 Smole, Sandra C.
A1 Madoff, Lawrence C.
A1 Ivers, Louise C.
YR 2021
UL http://medrxiv.org/content/early/2021/06/20/2021.06.17.21259109.abstract
AB Background Point-of-care antigen-detecting rapid diagnostic tests (RDTs) for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) represent a scalable tool for SARS-CoV-2 infections surveillance. Data on their performance in real-world community settings is paramount for their implementation.Method We evaluated the accuracy of CareStart™ COVID-19 Antigen test (CareStart) in a testing site in Holyoke, Massachusetts. We compared CareStart to a SARS-CoV-2 reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) reference, using anterior nasal swab samples. We calculated the sensitivity, specificity, and expected positive and negative predictive values at different SARS-CoV-2 prevalence estimates.Results We performed 666 tests on 591 unique individuals. 573 (86%) were asymptomatic. There were 52 positive tests by RT-qPCR. The sensitivity of CareStart was 49.0% (95% Confidence Interval (CI): 34.8 – 63.4) and specificity was 99.5% (95% CI: 98.5 – 99.9). Among positive RT-qPCR tests, the median cycle threshold (Ct) was significantly lower in samples that tested positive on CareStart. Using a Ct ≤ 30 as a benchmark for positivity increased the sensitivity to 64.9% (95% CI: 47.5 – 79.8).Conclusions CareStart has a high specificity and moderate sensitivity. The utility of RDTs, such as CareStart, in mass implementation should prioritize use cases in which a higher specificity is more important.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Holyoke Board of Health was instrumental in coordinating study logistics with Fallon Ambulance Services who performed the swabs for RT-qPCR. The MA Department of Public Health and Ginko Bioworks donated the Access Bio testing kits and anterior nares SteriPack swabs for this study. The study was supported by an award from the Massachusetts Life Sciences Center Accelerating Coronavirus Testing Solutions (A.C.T.S) and the Sullivan Family Foundation (LCI).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Verbal consent was obtained from participants to collect a second anterior nasal swab as well as from guardians of minors below 18 years of age, from whom verbal assent was also obtained. The participants were treated in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The study protocol was approved by the Partners Institutional Review Board (Protocol ID: 2020P003892).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary data, without any identifying individual information is reported in the manuscript's supplementary tables.